Japanese researchers have reported that zonisamide — an antiparkinsonian medicine approved in Japan as a combination therapy with levodopa — may be associated with a lower risk of dementia, insomnia, and gastric ulcers in Parkinson’s disease, compared with other non-levodopa medicines. Their research was published in the…
With the aim of transforming training and education for Parkinson’s disease and Lewy body dementia (LBD) caregivers and healthcare professionals, Embodied Labs has created a new virtual reality immersive learning lab. Embodied Labs allows caregivers and medical staff to embody a person with a specific condition, and…
Acupuncture may be beneficial to alleviate motor symptoms associated with Parkinson’s disease, according to data collected from mouse studies. The findings were published in the study, “Does Acupuncture Protect Dopamine Neurons in Parkinson’s Disease Rodent Model?: A Systematic Review and Meta-Analysis,”…
More than 1 in every 3 — some 40 percent — of Parkinson’s patients have “off periods,” the return of motor and non-motor symptoms as the effectiveness of a treatment’s dose wears off. Artworks created in collaboration with patients, part of an Acorda Therapeutics program, are helping to…
Parkinson’s disease-related protein Parkin may rely on another protein called MITOL to repair damaged mitochondria, the small organelles that provide energy to cells and, when defective, can damage brain nerve cells. Understanding these molecular mechanisms may help improve Parkinson’s therapies that intend to boost Parkin activity. The study…
A new study highlights some of the differences in perspective on disease management between people living with Parkinson’s disease and doctors treating them. The study looks at non-motor symptoms, method of medication delivery, and awareness of support services as places where doctors’ and patients’ perceptions don’t line up, and suggests…
Connexin-32 — a protein found in small channels between nerve cells and involved in cell-to-cell communication — works to progress Parkinson’s disease by binding to alpha-synuclein and spreading toxic protein clumps throughout the brain, research suggests. The study, “Binding of α-synuclein oligomers to Cx32 facilitates protein uptake and transfer in…
A Cleveland Clinic researcher is getting a $3 million grant from the National Institutes of Health (NIH) to study the long-term impact of high-intensity aerobic exercise on Parkinson’s disease progression. The five-year award goes to Jay Alberts, PhD, a staff member in the department of biomedical…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded Casma Therapeutics $370,000 to advance an innovative class of therapies aimed at slowing disease progression. The grant will promote the biotechnology company’s investigation into compounds that activate the calcium channel TRPML1 to accelerate autophagy…
UCB has announced the start of a Phase 1b clinical trial to evaluate the efficacy and safety of its therapeutic candidate UCB0599 for the treatment of Parkinson’s disease. This multicenter clinical trial will take place across the United States. Current treatments for Parkinson’s, which include…
Get regular updates to your inbox.
